FDA Releases New Resources for PMTA Amendments

Apr.13.2023
FDA Releases New Resources for PMTA Amendments
FDA provides resources to help prepare and submit revised PMTAs for tobacco products, including a guide and video tutorial.

The U.S. Food and Drug Administration's Center for Tobacco Products (CTP) has released two new resources to assist applicants in preparing and submitting revised pre-market tobacco product applications (PMTAs).


Explanation - Revision Note: Completion of FDA Form 4057a", "Video - Utilizing CTP Portal Website


The disclosure document provides a quick guide for filling out the FDA 4057a form for revising pre-market tobacco product applications and submitting general correspondence.


In most cases, the CTP can only review PMTA revisions that include the FDA 4057a form. When submitting a PMTA revision, the FDA will first review the required FDA 4057a form. If necessary information is missing from the form, the FDA may not continue with the review of the revision.


The video provides an overview of the CTP portal website and how to use it, including how to search for and track application submission numbers online.


References:


Newly Available Tools to Aid in PMTA Amendment Submission.


The video of the FDA tobacco compliance webinar.


Amendment Tips: How to fill out Form FDA 4057a.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Advocates say the economic authority’s decision contradicts national health goals and violates a Supreme Court directive banning new tobacco ventures.
Oct.27 by 2FIRSTS.ai
Research Brief | Nicotine pouch use among Canadian adolescents has drawn close to cigarettes
Research Brief | Nicotine pouch use among Canadian adolescents has drawn close to cigarettes
Study results show that nicotine pouches are the third most commonly used nicotine product among adolescents. Current use stands at 2.6%, close to cigarettes (3.0%). Risk of use is higher among cisgender boys, gender-diverse youth, students with poor academic performance, and those with part-time jobs; more than 70% of nicotine-pouch users also vape.
Sep.04 by 2FIRSTS.ai
Philip Morris Korea Extends IQOS ILUMA i Warranty to 18 Months, Says Move Will Boost Smoke-Free Product Growth
Philip Morris Korea Extends IQOS ILUMA i Warranty to 18 Months, Says Move Will Boost Smoke-Free Product Growth
Philip Morris International’s Korea unit has extended the warranty for the “IQOS ILUMA i” heated tobacco series from 12 to 18 months, applying it retroactively to existing purchases, aiming to enhance user experience and market competitiveness.
Oct.15 by 2FIRSTS.ai
Elf Bar Parent iMiracle to Pull Flavored Vapes From California, Ending Altria Unit NJOY Lawsuit
Elf Bar Parent iMiracle to Pull Flavored Vapes From California, Ending Altria Unit NJOY Lawsuit
China’s e-cigarette maker iMiracle, parent company of the Elf Bar brand, has agreed to halt sales of all flavored vaping products in California as part of a settlement with Altria Group’s e-cigarette unit, NJOY LLC, marking the end of a nearly two-year legal dispute.
Oct.13
Company | Philip Morris CEO: Expected profit growth in 2025 will be the highest in over a decade, with ZYN US retail sales up 32%
Company | Philip Morris CEO: Expected profit growth in 2025 will be the highest in over a decade, with ZYN US retail sales up 32%
At the 2025 Barclays Global Consumer Conference, Philip Morris International's CEO said that strong summer sales of IQOS and ZYN will boost the company's full-year 2025 adjusted EPS by 13% to 15%, the best performance since 2011 (excluding pandemic recovery). He also noted that IQOS has maintained strong growth in Q3, with ZYN sales up about 32% in the first eight weeks. The full-year shipment volume is expected to be between 800 million and 840 million cans.
Sep.03 by 2FIRSTS.ai
South Korea Plans Unified Regulation for Synthetic and Look-Alike Nicotine Products
South Korea Plans Unified Regulation for Synthetic and Look-Alike Nicotine Products
South Korea Parliament discusses including "nicotine" in Tobacco Business Act; synthetic nicotine testing method established, awaiting legislation approval.
Oct.22 by 2FIRSTS.ai